Skip to search formSkip to main contentSkip to account menu

Metharmon F

Known as: Androst-4-ene-3,17-dione, mixt. with (3beta,17beta)-androst-5-ene-3,17-diol, desiccated thyroid hormones, (17beta)-17-hydroxyandrost-4-en-3-one, 3-hydroxyestra-1,3,5(10)-trien-17-one and (3beta)-3-hydroxypregn-5-en-20-one 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (7)

AndrostenediolAndrostenedioneDrug CombinationsEstrone

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1988
1988
Clinical effect of Metharmon-F in middle-aged females with lump sensation in the throat.
Fifty-one famales with lump sensation in the throat were treated with Metharmon®-F.The overall effectiveness was excellent in 9… 
1986
1986
Clinical effect of Metharmon-F on climacterium patients with otorhinolaryngological unidentified clinical syndrome.
The clinical effects of Metharmon®-F were evaluated in 91 patients with climacteric disorders consisting mainly of… 
1986
1986
Clinical effects of Metharmon-F in middle-aged females with abnormal sensation in the pharyngolaryngeal region.
The clinical effects of Metharmon®-F were evaluated in 33 females aged 30 to 60 years with abnormal sensation in the… 
1973
1973
86. 不妊症に対する Metharmon-F の内分泌的検討と臨床成績
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)